NCT00031564View on ClinicalTrials.gov

Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2012

Conditions
Kidney Cancer
Interventions
BIOLOGICAL

Interleukin-2

BIOLOGICAL

B7-1

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Chiron Corporation
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Chiron Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER